RxDoctor Payments DataLook up a doctor →

David McDonald, MD

Diagnostic Neuroimaging · Ormond Beach, FLNPI 1104846815

Payments from drug & device makers

$1,332,009in general payments, 2019–2025

Across 1,152 payments — averaging $1156.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$759K
  • Eisai Inc.$472K
  • E.r. Squibb & Sons, L.L.C.$52K
  • Novartis$33K
  • Avanir Pharmaceuticals, Inc.$5K
  • MDD US Operations, LLC$909
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)246$758,664
Eisai Inc.232$472,221
E.r. Squibb & Sons, L.L.C.4$51,781
Novartis73$32,569
Avanir Pharmaceuticals, Inc.10$4,501
MDD US Operations, LLC28$909
Biogen44$763
EMD Serono, Inc.44$664
Argenx US, Inc.18$600
CSL Behring23$552
Teva Pharmaceuticals USA, Inc.31$537
Amgen(2 entities)30$528
Mallinckrodt Hospital Products Inc.8$499
Pfizer29$494
AstraZeneca20$477
UCB, Inc.17$474
Sanofi24$450
SK Life Science, Inc.17$432
Lilly USA, LLC20$418
Neurocrine Biosciences, Inc.16$399
Acadia Pharmaceuticals Inc21$362
Acorda Therapeutics, Inc18$338
Jazz Pharmaceuticals Inc.14$326
Genentech USA, Inc.21$307
Greenwich Biosciences, Inc.16$269
Sunovion Pharmaceuticals Inc.12$237
Biohaven Pharmaceutical Holding Company Ltd.12$228
Corium, LLC8$178
Amneal Pharmaceuticals LLC10$176
Otsuka America Pharmaceutical, Inc.7$165
ANI Pharmaceuticals, Inc.6$163
Lundbeck LLC7$127
GE HealthCare5$105
Bristol Myers Squibb6$101
Octapharma USA, Inc.3$76
Takeda Pharmaceuticals U.S.A., Inc.3$74
Neurelis, Inc.4$71
Adamas Pharmaceuticals, Inc.5$66
Vanda Pharmaceuticals Inc.3$66
Johnson & Johnson(2 entities)3$49
Banner Life Sciences, LLC2$48
Biohaven Pharmaceuticals, Inc.3$44
TG Therapeutics, Inc.2$40
Alnylam Pharmaceuticals Inc.2$38
Arbor Pharmaceuticals, Inc.3$37
Catalyst Pharmaceuticals, Inc.1$30
Cycle Pharmaceuticals Inc2$29
Avion Pharmaceuticals2$29
Grifols USA, LLC1$27
Portola Pharmaceuticals, LLC2$23
Kyowa Kirin, Inc.1$23
Microtransponder, Inc.1$22
Impel Pharmaceuticals Inc.1$20
Scilex Pharmaceuticals Inc.1$20
Merz North America, Inc.1$18
Boston Scientific1$18
Mallinckrodt Enterprises LLC1$17
Sanofi-aventis U.S. LLC1$16
Dynasplint Systems Inc.1$16
Neuronetics, Inc.1$16

How this compares

Too few diagnostic neuroimaging providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$228,470
Medicare patients
639
Services billed
1,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other diagnostic neuroimaging in Ormond Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →